acenocumarol

Phase 3Small molecule

HHospital Universitari Vall d'Hebron Research Institute

acenocumarol is one of 22 small molecule programs targeting Antiphospholipid Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Antiphospholipid SyndromeActive, not recruiting

Antiphospholipid SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

29 competitors in Antiphospholipid Syndrome

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Coumadin

AAbbott

Approved

3 3

Plaquenil

Alnylam Pharmaceuticals

Phase 3

3 4

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Approved

1 5

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 3

1 6

Lovenox

Sanofi

Phase 2

1 7

Lescol

Novartis

Phase 2

1 8

Rituxan

Roche

Phase 2

1 9

Darzalex

Johnson & Johnson

Phase 2

1 10

Rapamune

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Antiphospholipid Syndrome1 trial

Rivaroxaban for Patients With Antiphospholipid Syndrome

Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 3·NCT02926170·190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for acenocumarol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — acenocumarol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for acenocumarol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Universitari Vall d'Hebron Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHospital Universitari Vall d'Hebron Research Institute

acenocumarol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Antiphospholipid Syndrome1 trial

References

Drug Info

Quick Facts

Related News